Global Anaplastic Thyroid Cancer Drug Market Growth 2025-2031

October 2025 | 104 pages | ID: GBB6A47EEDA5EN
LP Information

Abstracts

The global Anaplastic Thyroid Cancer Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LP Information, Inc. (LPI) ' newest research report, the ?Anaplastic Thyroid Cancer Drug Industry Forecast? looks at past sales and reviews total world Anaplastic Thyroid Cancer Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Anaplastic Thyroid Cancer Drug sales for 2025 through 2031. With Anaplastic Thyroid Cancer Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anaplastic Thyroid Cancer Drug industry.

This Insight Report provides a comprehensive analysis of the global Anaplastic Thyroid Cancer Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anaplastic Thyroid Cancer Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Anaplastic Thyroid Cancer Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anaplastic Thyroid Cancer Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anaplastic Thyroid Cancer Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Anaplastic Thyroid Cancer Drug market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• CLM-94
• Crolibulin
• Efatutazone
• GLONC-2
• Others

Segmentation by Application:

• Hospital
• Clinic
• Others

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• Daiichi Sankyo Company, Limited
• Genelux Corporation
• Immune Pharmaceuticals Inc.
• Millennium Pharmaceuticals Inc
• Novartis AG
• Pfizer Inc.
• Plexxikon Inc.
• Trophogen, Inc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Anaplastic Thyroid Cancer Drug market?
What factors are driving Anaplastic Thyroid Cancer Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Anaplastic Thyroid Cancer Drug market opportunities vary by end market size?
How does Anaplastic Thyroid Cancer Drug break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Anaplastic Thyroid Cancer Drug Annual Sales 2020-2031
  2.1.2 World Current & Future Analysis for Anaplastic Thyroid Cancer Drug by Geographic Region, 2020, 2024 & 2031
  2.1.3 World Current & Future Analysis for Anaplastic Thyroid Cancer Drug by Country/Region, 2020, 2024 & 2031
2.2 Anaplastic Thyroid Cancer Drug Segment by Type
  2.2.1 CLM-94
  2.2.2 Crolibulin
  2.2.3 Efatutazone
  2.2.4 GLONC-2
  2.2.5 Others
2.3 Anaplastic Thyroid Cancer Drug Sales by Type
  2.3.1 Global Anaplastic Thyroid Cancer Drug Sales Market Share by Type (2020-2025)
  2.3.2 Global Anaplastic Thyroid Cancer Drug Revenue and Market Share by Type (2020-2025)
  2.3.3 Global Anaplastic Thyroid Cancer Drug Sale Price by Type (2020-2025)
2.4 Anaplastic Thyroid Cancer Drug Segment by Application
  2.4.1 Hospital
  2.4.2 Clinic
  2.4.3 Others
2.5 Anaplastic Thyroid Cancer Drug Sales by Application
  2.5.1 Global Anaplastic Thyroid Cancer Drug Sale Market Share by Application (2020-2025)
  2.5.2 Global Anaplastic Thyroid Cancer Drug Revenue and Market Share by Application (2020-2025)
  2.5.3 Global Anaplastic Thyroid Cancer Drug Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Anaplastic Thyroid Cancer Drug Breakdown Data by Company
  3.1.1 Global Anaplastic Thyroid Cancer Drug Annual Sales by Company (2020-2025)
  3.1.2 Global Anaplastic Thyroid Cancer Drug Sales Market Share by Company (2020-2025)
3.2 Global Anaplastic Thyroid Cancer Drug Annual Revenue by Company (2020-2025)
  3.2.1 Global Anaplastic Thyroid Cancer Drug Revenue by Company (2020-2025)
  3.2.2 Global Anaplastic Thyroid Cancer Drug Revenue Market Share by Company (2020-2025)
3.3 Global Anaplastic Thyroid Cancer Drug Sale Price by Company
3.4 Key Manufacturers Anaplastic Thyroid Cancer Drug Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Anaplastic Thyroid Cancer Drug Product Location Distribution
  3.4.2 Players Anaplastic Thyroid Cancer Drug Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR ANAPLASTIC THYROID CANCER DRUG BY GEOGRAPHIC REGION

4.1 World Historic Anaplastic Thyroid Cancer Drug Market Size by Geographic Region (2020-2025)
  4.1.1 Global Anaplastic Thyroid Cancer Drug Annual Sales by Geographic Region (2020-2025)
  4.1.2 Global Anaplastic Thyroid Cancer Drug Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Anaplastic Thyroid Cancer Drug Market Size by Country/Region (2020-2025)
  4.2.1 Global Anaplastic Thyroid Cancer Drug Annual Sales by Country/Region (2020-2025)
  4.2.2 Global Anaplastic Thyroid Cancer Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Anaplastic Thyroid Cancer Drug Sales Growth
4.4 APAC Anaplastic Thyroid Cancer Drug Sales Growth
4.5 Europe Anaplastic Thyroid Cancer Drug Sales Growth
4.6 Middle East & Africa Anaplastic Thyroid Cancer Drug Sales Growth

5 AMERICAS

5.1 Americas Anaplastic Thyroid Cancer Drug Sales by Country
  5.1.1 Americas Anaplastic Thyroid Cancer Drug Sales by Country (2020-2025)
  5.1.2 Americas Anaplastic Thyroid Cancer Drug Revenue by Country (2020-2025)
5.2 Americas Anaplastic Thyroid Cancer Drug Sales by Type (2020-2025)
5.3 Americas Anaplastic Thyroid Cancer Drug Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Anaplastic Thyroid Cancer Drug Sales by Region
  6.1.1 APAC Anaplastic Thyroid Cancer Drug Sales by Region (2020-2025)
  6.1.2 APAC Anaplastic Thyroid Cancer Drug Revenue by Region (2020-2025)
6.2 APAC Anaplastic Thyroid Cancer Drug Sales by Type (2020-2025)
6.3 APAC Anaplastic Thyroid Cancer Drug Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Anaplastic Thyroid Cancer Drug by Country
  7.1.1 Europe Anaplastic Thyroid Cancer Drug Sales by Country (2020-2025)
  7.1.2 Europe Anaplastic Thyroid Cancer Drug Revenue by Country (2020-2025)
7.2 Europe Anaplastic Thyroid Cancer Drug Sales by Type (2020-2025)
7.3 Europe Anaplastic Thyroid Cancer Drug Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Anaplastic Thyroid Cancer Drug by Country
  8.1.1 Middle East & Africa Anaplastic Thyroid Cancer Drug Sales by Country (2020-2025)
  8.1.2 Middle East & Africa Anaplastic Thyroid Cancer Drug Revenue by Country (2020-2025)
8.2 Middle East & Africa Anaplastic Thyroid Cancer Drug Sales by Type (2020-2025)
8.3 Middle East & Africa Anaplastic Thyroid Cancer Drug Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Anaplastic Thyroid Cancer Drug
10.3 Manufacturing Process Analysis of Anaplastic Thyroid Cancer Drug
10.4 Industry Chain Structure of Anaplastic Thyroid Cancer Drug

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Anaplastic Thyroid Cancer Drug Distributors
11.3 Anaplastic Thyroid Cancer Drug Customer

12 WORLD FORECAST REVIEW FOR ANAPLASTIC THYROID CANCER DRUG BY GEOGRAPHIC REGION

12.1 Global Anaplastic Thyroid Cancer Drug Market Size Forecast by Region
  12.1.1 Global Anaplastic Thyroid Cancer Drug Forecast by Region (2026-2031)
  12.1.2 Global Anaplastic Thyroid Cancer Drug Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Anaplastic Thyroid Cancer Drug Forecast by Type (2026-2031)
12.7 Global Anaplastic Thyroid Cancer Drug Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Daiichi Sankyo Company, Limited
  13.1.1 Daiichi Sankyo Company, Limited Company Information
  13.1.2 Daiichi Sankyo Company, Limited Anaplastic Thyroid Cancer Drug Product Portfolios and Specifications
  13.1.3 Daiichi Sankyo Company, Limited Anaplastic Thyroid Cancer Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.1.4 Daiichi Sankyo Company, Limited Main Business Overview
  13.1.5 Daiichi Sankyo Company, Limited Latest Developments
13.2 Genelux Corporation
  13.2.1 Genelux Corporation Company Information
  13.2.2 Genelux Corporation Anaplastic Thyroid Cancer Drug Product Portfolios and Specifications
  13.2.3 Genelux Corporation Anaplastic Thyroid Cancer Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.2.4 Genelux Corporation Main Business Overview
  13.2.5 Genelux Corporation Latest Developments
13.3 Immune Pharmaceuticals Inc.
  13.3.1 Immune Pharmaceuticals Inc. Company Information
  13.3.2 Immune Pharmaceuticals Inc. Anaplastic Thyroid Cancer Drug Product Portfolios and Specifications
  13.3.3 Immune Pharmaceuticals Inc. Anaplastic Thyroid Cancer Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.3.4 Immune Pharmaceuticals Inc. Main Business Overview
  13.3.5 Immune Pharmaceuticals Inc. Latest Developments
13.4 Millennium Pharmaceuticals Inc
  13.4.1 Millennium Pharmaceuticals Inc Company Information
  13.4.2 Millennium Pharmaceuticals Inc Anaplastic Thyroid Cancer Drug Product Portfolios and Specifications
  13.4.3 Millennium Pharmaceuticals Inc Anaplastic Thyroid Cancer Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.4.4 Millennium Pharmaceuticals Inc Main Business Overview
  13.4.5 Millennium Pharmaceuticals Inc Latest Developments
13.5 Novartis AG
  13.5.1 Novartis AG Company Information
  13.5.2 Novartis AG Anaplastic Thyroid Cancer Drug Product Portfolios and Specifications
  13.5.3 Novartis AG Anaplastic Thyroid Cancer Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.5.4 Novartis AG Main Business Overview
  13.5.5 Novartis AG Latest Developments
13.6 Pfizer Inc.
  13.6.1 Pfizer Inc. Company Information
  13.6.2 Pfizer Inc. Anaplastic Thyroid Cancer Drug Product Portfolios and Specifications
  13.6.3 Pfizer Inc. Anaplastic Thyroid Cancer Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.6.4 Pfizer Inc. Main Business Overview
  13.6.5 Pfizer Inc. Latest Developments
13.7 Plexxikon Inc.
  13.7.1 Plexxikon Inc. Company Information
  13.7.2 Plexxikon Inc. Anaplastic Thyroid Cancer Drug Product Portfolios and Specifications
  13.7.3 Plexxikon Inc. Anaplastic Thyroid Cancer Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.7.4 Plexxikon Inc. Main Business Overview
  13.7.5 Plexxikon Inc. Latest Developments
13.8 Trophogen, Inc.
  13.8.1 Trophogen, Inc. Company Information
  13.8.2 Trophogen, Inc. Anaplastic Thyroid Cancer Drug Product Portfolios and Specifications
  13.8.3 Trophogen, Inc. Anaplastic Thyroid Cancer Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.8.4 Trophogen, Inc. Main Business Overview
  13.8.5 Trophogen, Inc. Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Anaplastic Thyroid Cancer Drug Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Anaplastic Thyroid Cancer Drug Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of CLM-94
Table 4. Major Players of Crolibulin
Table 5. Major Players of Efatutazone
Table 6. Major Players of GLONC-2
Table 7. Major Players of Others
Table 8. Global Anaplastic Thyroid Cancer Drug Sales by Type (2020-2025) & (K Pcs)
Table 9. Global Anaplastic Thyroid Cancer Drug Sales Market Share by Type (2020-2025)
Table 10. Global Anaplastic Thyroid Cancer Drug Revenue by Type (2020-2025) & ($ million)
Table 11. Global Anaplastic Thyroid Cancer Drug Revenue Market Share by Type (2020-2025)
Table 12. Global Anaplastic Thyroid Cancer Drug Sale Price by Type (2020-2025) & (USD/Pcs)
Table 13. Global Anaplastic Thyroid Cancer Drug Sale by Application (2020-2025) & (K Pcs)
Table 14. Global Anaplastic Thyroid Cancer Drug Sale Market Share by Application (2020-2025)
Table 15. Global Anaplastic Thyroid Cancer Drug Revenue by Application (2020-2025) & ($ million)
Table 16. Global Anaplastic Thyroid Cancer Drug Revenue Market Share by Application (2020-2025)
Table 17. Global Anaplastic Thyroid Cancer Drug Sale Price by Application (2020-2025) & (USD/Pcs)
Table 18. Global Anaplastic Thyroid Cancer Drug Sales by Company (2020-2025) & (K Pcs)
Table 19. Global Anaplastic Thyroid Cancer Drug Sales Market Share by Company (2020-2025)
Table 20. Global Anaplastic Thyroid Cancer Drug Revenue by Company (2020-2025) & ($ millions)
Table 21. Global Anaplastic Thyroid Cancer Drug Revenue Market Share by Company (2020-2025)
Table 22. Global Anaplastic Thyroid Cancer Drug Sale Price by Company (2020-2025) & (USD/Pcs)
Table 23. Key Manufacturers Anaplastic Thyroid Cancer Drug Producing Area Distribution and Sales Area
Table 24. Players Anaplastic Thyroid Cancer Drug Products Offered
Table 25. Anaplastic Thyroid Cancer Drug Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global Anaplastic Thyroid Cancer Drug Sales by Geographic Region (2020-2025) & (K Pcs)
Table 29. Global Anaplastic Thyroid Cancer Drug Sales Market Share Geographic Region (2020-2025)
Table 30. Global Anaplastic Thyroid Cancer Drug Revenue by Geographic Region (2020-2025) & ($ millions)
Table 31. Global Anaplastic Thyroid Cancer Drug Revenue Market Share by Geographic Region (2020-2025)
Table 32. Global Anaplastic Thyroid Cancer Drug Sales by Country/Region (2020-2025) & (K Pcs)
Table 33. Global Anaplastic Thyroid Cancer Drug Sales Market Share by Country/Region (2020-2025)
Table 34. Global Anaplastic Thyroid Cancer Drug Revenue by Country/Region (2020-2025) & ($ millions)
Table 35. Global Anaplastic Thyroid Cancer Drug Revenue Market Share by Country/Region (2020-2025)
Table 36. Americas Anaplastic Thyroid Cancer Drug Sales by Country (2020-2025) & (K Pcs)
Table 37. Americas Anaplastic Thyroid Cancer Drug Sales Market Share by Country (2020-2025)
Table 38. Americas Anaplastic Thyroid Cancer Drug Revenue by Country (2020-2025) & ($ millions)
Table 39. Americas Anaplastic Thyroid Cancer Drug Sales by Type (2020-2025) & (K Pcs)
Table 40. Americas Anaplastic Thyroid Cancer Drug Sales by Application (2020-2025) & (K Pcs)
Table 41. APAC Anaplastic Thyroid Cancer Drug Sales by Region (2020-2025) & (K Pcs)
Table 42. APAC Anaplastic Thyroid Cancer Drug Sales Market Share by Region (2020-2025)
Table 43. APAC Anaplastic Thyroid Cancer Drug Revenue by Region (2020-2025) & ($ millions)
Table 44. APAC Anaplastic Thyroid Cancer Drug Sales by Type (2020-2025) & (K Pcs)
Table 45. APAC Anaplastic Thyroid Cancer Drug Sales by Application (2020-2025) & (K Pcs)
Table 46. Europe Anaplastic Thyroid Cancer Drug Sales by Country (2020-2025) & (K Pcs)
Table 47. Europe Anaplastic Thyroid Cancer Drug Revenue by Country (2020-2025) & ($ millions)
Table 48. Europe Anaplastic Thyroid Cancer Drug Sales by Type (2020-2025) & (K Pcs)
Table 49. Europe Anaplastic Thyroid Cancer Drug Sales by Application (2020-2025) & (K Pcs)
Table 50. Middle East & Africa Anaplastic Thyroid Cancer Drug Sales by Country (2020-2025) & (K Pcs)
Table 51. Middle East & Africa Anaplastic Thyroid Cancer Drug Revenue Market Share by Country (2020-2025)
Table 52. Middle East & Africa Anaplastic Thyroid Cancer Drug Sales by Type (2020-2025) & (K Pcs)
Table 53. Middle East & Africa Anaplastic Thyroid Cancer Drug Sales by Application (2020-2025) & (K Pcs)
Table 54. Key Market Drivers & Growth Opportunities of Anaplastic Thyroid Cancer Drug
Table 55. Key Market Challenges & Risks of Anaplastic Thyroid Cancer Drug
Table 56. Key Industry Trends of Anaplastic Thyroid Cancer Drug
Table 57. Anaplastic Thyroid Cancer Drug Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. Anaplastic Thyroid Cancer Drug Distributors List
Table 60. Anaplastic Thyroid Cancer Drug Customer List
Table 61. Global Anaplastic Thyroid Cancer Drug Sales Forecast by Region (2026-2031) & (K Pcs)
Table 62. Global Anaplastic Thyroid Cancer Drug Revenue Forecast by Region (2026-2031) & ($ millions)
Table 63. Americas Anaplastic Thyroid Cancer Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 64. Americas Anaplastic Thyroid Cancer Drug Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 65. APAC Anaplastic Thyroid Cancer Drug Sales Forecast by Region (2026-2031) & (K Pcs)
Table 66. APAC Anaplastic Thyroid Cancer Drug Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 67. Europe Anaplastic Thyroid Cancer Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 68. Europe Anaplastic Thyroid Cancer Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Middle East & Africa Anaplastic Thyroid Cancer Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 70. Middle East & Africa Anaplastic Thyroid Cancer Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 71. Global Anaplastic Thyroid Cancer Drug Sales Forecast by Type (2026-2031) & (K Pcs)
Table 72. Global Anaplastic Thyroid Cancer Drug Revenue Forecast by Type (2026-2031) & ($ millions)
Table 73. Global Anaplastic Thyroid Cancer Drug Sales Forecast by Application (2026-2031) & (K Pcs)
Table 74. Global Anaplastic Thyroid Cancer Drug Revenue Forecast by Application (2026-2031) & ($ millions)
Table 75. Daiichi Sankyo Company, Limited Basic Information, Anaplastic Thyroid Cancer Drug Manufacturing Base, Sales Area and Its Competitors
Table 76. Daiichi Sankyo Company, Limited Anaplastic Thyroid Cancer Drug Product Portfolios and Specifications
Table 77. Daiichi Sankyo Company, Limited Anaplastic Thyroid Cancer Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 78. Daiichi Sankyo Company, Limited Main Business
Table 79. Daiichi Sankyo Company, Limited Latest Developments
Table 80. Genelux Corporation Basic Information, Anaplastic Thyroid Cancer Drug Manufacturing Base, Sales Area and Its Competitors
Table 81. Genelux Corporation Anaplastic Thyroid Cancer Drug Product Portfolios and Specifications
Table 82. Genelux Corporation Anaplastic Thyroid Cancer Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 83. Genelux Corporation Main Business
Table 84. Genelux Corporation Latest Developments
Table 85. Immune Pharmaceuticals Inc. Basic Information, Anaplastic Thyroid Cancer Drug Manufacturing Base, Sales Area and Its Competitors
Table 86. Immune Pharmaceuticals Inc. Anaplastic Thyroid Cancer Drug Product Portfolios and Specifications
Table 87. Immune Pharmaceuticals Inc. Anaplastic Thyroid Cancer Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 88. Immune Pharmaceuticals Inc. Main Business
Table 89. Immune Pharmaceuticals Inc. Latest Developments
Table 90. Millennium Pharmaceuticals Inc Basic Information, Anaplastic Thyroid Cancer Drug Manufacturing Base, Sales Area and Its Competitors
Table 91. Millennium Pharmaceuticals Inc Anaplastic Thyroid Cancer Drug Product Portfolios and Specifications
Table 92. Millennium Pharmaceuticals Inc Anaplastic Thyroid Cancer Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 93. Millennium Pharmaceuticals Inc Main Business
Table 94. Millennium Pharmaceuticals Inc Latest Developments
Table 95. Novartis AG Basic Information, Anaplastic Thyroid Cancer Drug Manufacturing Base, Sales Area and Its Competitors
Table 96. Novartis AG Anaplastic Thyroid Cancer Drug Product Portfolios and Specifications
Table 97. Novartis AG Anaplastic Thyroid Cancer Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 98. Novartis AG Main Business
Table 99. Novartis AG Latest Developments
Table 100. Pfizer Inc. Basic Information, Anaplastic Thyroid Cancer Drug Manufacturing Base, Sales Area and Its Competitors
Table 101. Pfizer Inc. Anaplastic Thyroid Cancer Drug Product Portfolios and Specifications
Table 102. Pfizer Inc. Anaplastic Thyroid Cancer Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 103. Pfizer Inc. Main Business
Table 104. Pfizer Inc. Latest Developments
Table 105. Plexxikon Inc. Basic Information, Anaplastic Thyroid Cancer Drug Manufacturing Base, Sales Area and Its Competitors
Table 106. Plexxikon Inc. Anaplastic Thyroid Cancer Drug Product Portfolios and Specifications
Table 107. Plexxikon Inc. Anaplastic Thyroid Cancer Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 108. Plexxikon Inc. Main Business
Table 109. Plexxikon Inc. Latest Developments
Table 110. Trophogen, Inc. Basic Information, Anaplastic Thyroid Cancer Drug Manufacturing Base, Sales Area and Its Competitors
Table 111. Trophogen, Inc. Anaplastic Thyroid Cancer Drug Product Portfolios and Specifications
Table 112. Trophogen, Inc. Anaplastic Thyroid Cancer Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 113. Trophogen, Inc. Main Business
Table 114. Trophogen, Inc. Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Anaplastic Thyroid Cancer Drug
Figure 2. Anaplastic Thyroid Cancer Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Anaplastic Thyroid Cancer Drug Sales Growth Rate 2020-2031 (K Pcs)
Figure 7. Global Anaplastic Thyroid Cancer Drug Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Anaplastic Thyroid Cancer Drug Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Anaplastic Thyroid Cancer Drug Sales Market Share by Country/Region (2024)
Figure 10. Anaplastic Thyroid Cancer Drug Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of CLM-94
Figure 12. Product Picture of Crolibulin
Figure 13. Product Picture of Efatutazone
Figure 14. Product Picture of GLONC-2
Figure 15. Product Picture of Others
Figure 16. Global Anaplastic Thyroid Cancer Drug Sales Market Share by Type in 2025
Figure 17. Global Anaplastic Thyroid Cancer Drug Revenue Market Share by Type (2020-2025)
Figure 18. Anaplastic Thyroid Cancer Drug Consumed in Hospital
Figure 19. Global Anaplastic Thyroid Cancer Drug Market: Hospital (2020-2025) & (K Pcs)
Figure 20. Anaplastic Thyroid Cancer Drug Consumed in Clinic
Figure 21. Global Anaplastic Thyroid Cancer Drug Market: Clinic (2020-2025) & (K Pcs)
Figure 22. Anaplastic Thyroid Cancer Drug Consumed in Others
Figure 23. Global Anaplastic Thyroid Cancer Drug Market: Others (2020-2025) & (K Pcs)
Figure 24. Global Anaplastic Thyroid Cancer Drug Sale Market Share by Application (2024)
Figure 25. Global Anaplastic Thyroid Cancer Drug Revenue Market Share by Application in 2025
Figure 26. Anaplastic Thyroid Cancer Drug Sales by Company in 2025 (K Pcs)
Figure 27. Global Anaplastic Thyroid Cancer Drug Sales Market Share by Company in 2025
Figure 28. Anaplastic Thyroid Cancer Drug Revenue by Company in 2025 ($ millions)
Figure 29. Global Anaplastic Thyroid Cancer Drug Revenue Market Share by Company in 2025
Figure 30. Global Anaplastic Thyroid Cancer Drug Sales Market Share by Geographic Region (2020-2025)
Figure 31. Global Anaplastic Thyroid Cancer Drug Revenue Market Share by Geographic Region in 2025
Figure 32. Americas Anaplastic Thyroid Cancer Drug Sales 2020-2025 (K Pcs)
Figure 33. Americas Anaplastic Thyroid Cancer Drug Revenue 2020-2025 ($ millions)
Figure 34. APAC Anaplastic Thyroid Cancer Drug Sales 2020-2025 (K Pcs)
Figure 35. APAC Anaplastic Thyroid Cancer Drug Revenue 2020-2025 ($ millions)
Figure 36. Europe Anaplastic Thyroid Cancer Drug Sales 2020-2025 (K Pcs)
Figure 37. Europe Anaplastic Thyroid Cancer Drug Revenue 2020-2025 ($ millions)
Figure 38. Middle East & Africa Anaplastic Thyroid Cancer Drug Sales 2020-2025 (K Pcs)
Figure 39. Middle East & Africa Anaplastic Thyroid Cancer Drug Revenue 2020-2025 ($ millions)
Figure 40. Americas Anaplastic Thyroid Cancer Drug Sales Market Share by Country in 2025
Figure 41. Americas Anaplastic Thyroid Cancer Drug Revenue Market Share by Country (2020-2025)
Figure 42. Americas Anaplastic Thyroid Cancer Drug Sales Market Share by Type (2020-2025)
Figure 43. Americas Anaplastic Thyroid Cancer Drug Sales Market Share by Application (2020-2025)
Figure 44. United States Anaplastic Thyroid Cancer Drug Revenue Growth 2020-2025 ($ millions)
Figure 45. Canada Anaplastic Thyroid Cancer Drug Revenue Growth 2020-2025 ($ millions)
Figure 46. Mexico Anaplastic Thyroid Cancer Drug Revenue Growth 2020-2025 ($ millions)
Figure 47. Brazil Anaplastic Thyroid Cancer Drug Revenue Growth 2020-2025 ($ millions)
Figure 48. APAC Anaplastic Thyroid Cancer Drug Sales Market Share by Region in 2025
Figure 49. APAC Anaplastic Thyroid Cancer Drug Revenue Market Share by Region (2020-2025)
Figure 50. APAC Anaplastic Thyroid Cancer Drug Sales Market Share by Type (2020-2025)
Figure 51. APAC Anaplastic Thyroid Cancer Drug Sales Market Share by Application (2020-2025)
Figure 52. China Anaplastic Thyroid Cancer Drug Revenue Growth 2020-2025 ($ millions)
Figure 53. Japan Anaplastic Thyroid Cancer Drug Revenue Growth 2020-2025 ($ millions)
Figure 54. South Korea Anaplastic Thyroid Cancer Drug Revenue Growth 2020-2025 ($ millions)
Figure 55. Southeast Asia Anaplastic Thyroid Cancer Drug Revenue Growth 2020-2025 ($ millions)
Figure 56. India Anaplastic Thyroid Cancer Drug Revenue Growth 2020-2025 ($ millions)
Figure 57. Australia Anaplastic Thyroid Cancer Drug Revenue Growth 2020-2025 ($ millions)
Figure 58. China Taiwan Anaplastic Thyroid Cancer Drug Revenue Growth 2020-2025 ($ millions)
Figure 59. Europe Anaplastic Thyroid Cancer Drug Sales Market Share by Country in 2025
Figure 60. Europe Anaplastic Thyroid Cancer Drug Revenue Market Share by Country (2020-2025)
Figure 61. Europe Anaplastic Thyroid Cancer Drug Sales Market Share by Type (2020-2025)
Figure 62. Europe Anaplastic Thyroid Cancer Drug Sales Market Share by Application (2020-2025)
Figure 63. Germany Anaplastic Thyroid Cancer Drug Revenue Growth 2020-2025 ($ millions)
Figure 64. France Anaplastic Thyroid Cancer Drug Revenue Growth 2020-2025 ($ millions)
Figure 65. UK Anaplastic Thyroid Cancer Drug Revenue Growth 2020-2025 ($ millions)
Figure 66. Italy Anaplastic Thyroid Cancer Drug Revenue Growth 2020-2025 ($ millions)
Figure 67. Russia Anaplastic Thyroid Cancer Drug Revenue Growth 2020-2025 ($ millions)
Figure 68. Middle East & Africa Anaplastic Thyroid Cancer Drug Sales Market Share by Country (2020-2025)
Figure 69. Middle East & Africa Anaplastic Thyroid Cancer Drug Sales Market Share by Type (2020-2025)
Figure 70. Middle East & Africa Anaplastic Thyroid Cancer Drug Sales Market Share by Application (2020-2025)
Figure 71. Egypt Anaplastic Thyroid Cancer Drug Revenue Growth 2020-2025 ($ millions)
Figure 72. South Africa Anaplastic Thyroid Cancer Drug Revenue Growth 2020-2025 ($ millions)
Figure 73. Israel Anaplastic Thyroid Cancer Drug Revenue Growth 2020-2025 ($ millions)
Figure 74. Turkey Anaplastic Thyroid Cancer Drug Revenue Growth 2020-2025 ($ millions)
Figure 75. GCC Countries Anaplastic Thyroid Cancer Drug Revenue Growth 2020-2025 ($ millions)
Figure 76. Manufacturing Cost Structure Analysis of Anaplastic Thyroid Cancer Drug in 2025
Figure 77. Manufacturing Process Analysis of Anaplastic Thyroid Cancer Drug
Figure 78. Industry Chain Structure of Anaplastic Thyroid Cancer Drug
Figure 79. Channels of Distribution
Figure 80. Global Anaplastic Thyroid Cancer Drug Sales Market Forecast by Region (2026-2031)
Figure 81. Global Anaplastic Thyroid Cancer Drug Revenue Market Share Forecast by Region (2026-2031)
Figure 82. Global Anaplastic Thyroid Cancer Drug Sales Market Share Forecast by Type (2026-2031)
Figure 83. Global Anaplastic Thyroid Cancer Drug Revenue Market Share Forecast by Type (2026-2031)
Figure 84. Global Anaplastic Thyroid Cancer Drug Sales Market Share Forecast by Application (2026-2031)
Figure 85. Global Anaplastic Thyroid Cancer Drug Revenue Market Share Forecast by Application (2026-2031)